NYSE:MCKHealthcare
McKesson’s CMS Cancer Data Role And What It May Mean For Valuation
McKesson (NYSE:MCK) has been recognized by the Centers for Medicare & Medicaid Services as a Qualified Clinical Data Registry for the tenth consecutive year.
CMS is retaining McKesson’s Practice Insights QCDR measures for inclusion in the 2026 Advancing Cancer Care MIPS Value Pathways.
The company is expanding its role in advanced cancer care quality pathways, supporting data driven care standards for oncology practices.
For you as an investor, this development sits at the intersection of...